The effects of selected probiotic strains on the development of eczema (the PandA study)

Niers, Laetitia E. M.; Martı́n, Rocı́o; Rijkers, Ger T.; Sengers, F.; Timmerman, Harro M.; Uden, Nathalie O. van; Smidt, Hauke; Kimpen, Jan L. L.; Hoekstra, M. O.

doi:10.1111/j.1398-9995.2009.02021.x

Cited by 212 publications

(194 citation statements)

References 35 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…4 NO. 18 We found five studies including 191 patients that reported deaths as a result of SCC, 547,585,[588][589][590] with an average of 9.1% of patients dying from their disease on pooled analysis (95% CI 1.4% to 22.8%; I 2 = 79%) 23,67,[70][71][72] ( Figure 43). The greatest proportion of deaths was observed in a study of advanced T4 tumours in which two of three patients with eligible SCCs died (66%, 95% CI 9.4% to 99.1%) 590 during a mean follow-up period of 14 months.…”

Section: Squamous Cell Skin Cancer Work Programmementioning

confidence: 99%

“…early, late and prolonged formula feeding; exclusively breastfed, mixed breastfed or exclusively formula-fed; and high or normal risk for allergic disease) which makes it difficult to perform meta-analyses in such populations. Trials of prebiotic and probiotic interventions also suffered from large heterogeneity in the interventions and it should be noted that several probiotic trials have been published since the last systematic review on this subject, [62][63][64][65][66][67][68][69][70] warranting an updated review.…”

Section: Quality Of the Evidencementioning

confidence: 99%

“…The strength of some conclusions was limited by small numbers of trials or participants included in the relevant reviews and the analysis of probiotic effects was limited by the recent publication of many relevant trials [62][63][64][65][66][67][68][69][70] that have not yet been incorporated into a Cochrane systematic review. A more recent meta-analysis incorporating many of these trials 71 found that probiotic supplementation significantly reduces risk of developing eczema in infancy (RR 0.79, 95% CI 0.67 to 0.92), a finding supported by subsequent reviews.…”

Section: Limitationsmentioning

confidence: 99%

See 2 more Smart Citations

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

Section: Squamous Cell Skin Cancer Work Programmementioning

confidence: 99%

Section: Quality Of the Evidencementioning

confidence: 99%

Section: Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

show abstract

“…We have used ex vivo immune assays that are simple to implement in clinical trial settings. [25][26][27][28] Here, we report our promising results with an 8-week oral administration of the probiotic B. lactis NCC2818.…”

Section: Introductionmentioning

confidence: 99%

Immune-modulatory effect of probiotic Bifidobacterium lactis NCC2818 in individuals suffering from seasonal allergic rhinitis to grass pollen: an exploratory, randomized, placebo-controlled clinical trial

Singh

Hacini‐Rachinel

Gosoniu³

et al. 2013

Eur J Clin Nutr

View full text Add to dashboard Cite

BACKGROUND/OBJECTIVES: Probiotics are defined as 'living micro-organisms that when administered in adequate amounts confer a health benefit to the host'. Different probiotic strains have been investigated for beneficial effects on allergic disorders. The purpose of the current study was to evaluate the effect of orally administering the probiotic Nestlé culture collection (NCC)2818 Bifidobacterium lactis strain on immune parameters and nasal symptom scores in subjects suffering from seasonal allergic rhinitis (SAR). SUBJECTS/METHODS: The study was a double-blinded, parallel, randomized placebo-controlled trial conducted during the peak of the pollen season. Adult subjects with clinical history of SAR and positive skin prick test to grass pollen were recruited. The subjects received B. lactis NCC2818 or placebo for 8 weeks and completed symptom questionnaires every week. Whole blood was collected at baseline (V1), 4 weeks (V2) and 8 weeks (V3) to measure immune parameters. RESULTS: Concentrations of Th-2 cytokines, secreted by stimulated blood lymphocytes, were significantly lower in the probiotic group compared with the placebo group at V3 (interleukin (IL)-5, P ¼ 0.016; IL-13, P ¼ 0.005). Total nasal symptom scores were significantly lower in the second month of the study (weeks 5-8) in the probiotic group compared with the placebo group (P ¼ 0.03). Also, percentages of activated CD63 expressing basophils were significantly lower in the probiotic group at V2 (P ¼ 0.02). CONCLUSIONS: Oral administration of the probiotic NCC2818 mitigates immune parameters and allergic symptoms during seasonal exposure. These promising results warrant that B. lactis NCC2818 be investigated further in large-scale trials for management of respiratory allergy.

show abstract

“…So far, studies on the preventive effect of probiotic intake during pregnancy/lactation on allergic diseases have not been designed to specifically asses their effect on FA. However, some of them have looked at surrogate markers of FA as secondary outcomes, and their results are summarized in table 3.In 2009 Niers et al [78], conducted a double-blind, randomized, placebo-controlled (RDBPC) trial aimed to study the primary prevention of allergic disease in high-risk children by pre-and postnatal supplementation with probiotics. A mixture of three probiotic bacteria (Bifidobacteriumbifidum, B. lactis, and Lactococcuslactis) was administered to pregnant mothers during the last 6 weeks of pregnancy and postnatally for 12 months to their offspring.…”

mentioning

confidence: 99%

The Potential of Maternal Dietary Modification for Prevention of Food Allergy

Luengo¹,

Song²

2013

J Aller Ther

View full text Add to dashboard Cite

Effective primary preventions strategies aimed at reducing the onset of IgE sensitization are urgently needed as the incidence of childhood food allergy keeps increasing.Studies eliminating food allergens during pregnancy have failed to show reduction in the prevalence of long-term IgE-mediated food allergy in children, and recent data provides direct evidence supporting early oral exposure as a means of preventing development of allergy. Since effects on early immune programming may be more significant in utero, there has been increasing interest in the potential protective role of maternal dietary modifications on the development of FA in offspring.In this article, we will review the current knowledge from animal and clinical studies on the role of maternal dietary modification, mainly through supplementation with vitamins, polyunsaturated fatty acids and probiotics, for the prevention of food allergy. Besides, the potential role of some promising FA treatments like Chinese herbal formula FAHF-2 for the primary prevention of FA in offspring will be reviewed. be due to uncontrolled environmental factors, timing of introduction to PN and different study protocols and populations, as well as undefined co-factors in maternal diet such as microbes [18][19][20]. In addition, retrospective maternal recall of dietary intake during pregnancy (and or lactation), sometimes months or years later, may contain recall bias. At present, the standard practice for PNA and other food allergies is strict allergen avoidance. There is no clinical study reporting whether peanut allergic mother consumption of controlled low doses of peanut that do not trigger clinical reactions would prevent offspring peanut or other food allergies. The Potential of Maternal Dietary Modification for Prevention of Food AllergyOlga Maternal allergenic food consumption for preventing food allergy in offspring: Animal studiesIn recent years several studies in animal models have provided direct evidence supporting early oral exposure as a means of preventing development of allergy.Melkild et al. [21] showed that intraperitoneal immunization of naïve mice with ovalbumin and adjuvant (Al(OH) 3 ) during pregnancy and lactation significantly reduced the specific IgE response and increased the IgG2a response in their offspring. Moreover, the IgE suppression was stronger if maternal allergen exposure was during early pregnancy (3 days into pregnancy) compared to a late pregnancy exposure (17 days into pregnancy). The same group reported that the protective effect of maternal immunization was affected by the type of adjuvant used: while offspring from mothers immunized with OVA and either pertussis toxin (PT) or Al(OH) 3 showed reduced levels of OVA-specific IgE and IgG1 and increased levels of OVA-specific IgG2a antibodies, maternal immunization with CpG and OVA did not affect antibody responses in offspring [22]. However, whether this effect is dependent on the specific adjuvant and/or the route of exposure employed has to be further investigated. Le...

show abstract

The effects of selected probiotic strains on the development of eczema (the PandA study)

Cited by 212 publications

References 35 publications

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Immune-modulatory effect of probiotic Bifidobacterium lactis NCC2818 in individuals suffering from seasonal allergic rhinitis to grass pollen: an exploratory, randomized, placebo-controlled clinical trial

The Potential of Maternal Dietary Modification for Prevention of Food Allergy

Contact Info

Product

Resources

About